Search company, investor...
Spectroplast company logo


Founded Year



Incubator/Accelerator | Alive

Total Raised


About Spectroplast

Spectroplast provides digital silicone manufacturing solutions. It develops a three-dimensional (3D) printing process that can materialize silicone designs without the need for molds. The company was founded in 2018 and is based in Zurich, Switzerland.

Headquarters Location

Ruetistrasse 16

Zurich, 8952,


Missing: Spectroplast's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Spectroplast's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Spectroplast Patents

Spectroplast has filed 1 patent.

The 3 most popular patent topics include:

  • 3D printing
  • 3D printing processes
  • Food additives
patents chart

Application Date

Grant Date


Related Topics



3D printing processes, 3D printing, Fused filament fabrication, Food additives, Manufacturing


Application Date


Grant Date


Related Topics

3D printing processes, 3D printing, Fused filament fabrication, Food additives, Manufacturing



Latest Spectroplast News

Silicone 3D printer specialist completes Series A funding round

May 2, 2023

Silicone 3D printer specialist completes Series A funding round 0Shares Lynxter , a France-based 3D printer manufacturer, has announced a new financing round of 4 million Euros in series A funding. The funding will support Lynxter’s mission to develop innovative additive manufacturing solutions for industry, healthcare, and education. Since completing a seed round of €1.5 million in 2019, Lynxter has broadened its ecosystem and begun expanding into North America. Lynxter makes a range of 3D printers designed to use materials including carbon PA, PP, PEKK, polycarbonate, TPU, and porcelain. Where the company stands out is their ability to 3D print silicone. Lynxter describes their S300X 3D printer as, the “leading professional 3D printer for silicone and polyurethane additive manufacturing in medical and industrial sectors as well as R&D.” Existing investors and new partners, such as GE Invest, NACO, PG-Dev, and HERRIKOA, have joined the funding round. Lynxter intends to use the funding to export its innovations to additional countries, strengthen its team by adding approximately ten team members in 2023, and continue innovation, preserving and enhancing its research-based identity. Customers of Lynxter include major corporations like Airbus, Schneider, Sanofi, and Renault. A statement issued by the company stated, “Lynxter is grateful to all persons and entities who supported us throughout this important round of funding: The Line, INLO, and Aldearran Advisors have proven their effectiveness, value, and professionalism.” Lynxter 3D printing systems. Photo via Lynxter. Silicone 3D printing In 2019, German RepRap, now renamed innovatiQ , launched the L320, a Liquid Additive Manufacturing (LAM) 3D printing system with a larger build volume than its predecessor, the L280. Designed for processing 3D printing liquid silicone rubber, the L320 offers a highly stable system suitable for industrial continuous operation. Unlike traditional material extrusion technologies, LAM deposits liquid material, which is then vulcanized into a solid object through exposure to a heat lamp between layers. This method provides equal strength across the X, Y, and Z axes, making it suitable for both low-volume prototyping and serial production. The L320 has a print speed range of 10 to 150 mm/s, positional accuracy of +/- 0.2 mm/s, and can produce layer heights between 0.22 and 0.9 mm. Orthotics and prosthetics 3D printed by Spectroplast. Photo via Spectroplast. Also that year, 3D Printing Industry caught up with Spectroplast after the company won the Formnext Startup Challenge for their silicone 3D printing service . Spectroplast is a Swiss-based company founded in 2018 as a spinoff from ETH Zurich. They specialize in producing high-precision real silicone 3D prints. They position themselves as a complementary process to liquid injection molding, suitable for manufacturing small and medium series production of finished products and functional prototypes. Spectroplast is focused on the healthcare and medical sectors and plans to target necessary compliance certification for introducing a medically certified silicone material to the world of additive manufacturing. In 2021, The Digital Manufacturing Centre (DMC) in Silverstone Park became the UK’s first provider of silicone additive manufacturing (SAM) services, using a process developed by ETH Zurich spin-off Spectroplast. This 3D printing technique uses 100% biocompatible silicone as raw material, allowing for the production of personalized medical devices with minimal waste and lead times. The Spectroplast process, which is ISO DIN EN10993-05 and EN10993-10 certified, can cut lead times from six weeks to five days and reduce the overall cost per part by up to 50% for certain volumes. The technology is expected to have applications in the general engineering sector as well, such as gaskets, seals, and dampers. For all of the latest 3D printer releases subscribe to our  newsletter , follow us on  Twitter , and like us on  Facebook . Find talent for a project, or advance your career in 3D printing – join  3D Printing Jobs  to apply and advertise. Featured image shows the Lynxter Team. Photo via Lynxter.

Spectroplast Frequently Asked Questions (FAQ)

  • When was Spectroplast founded?

    Spectroplast was founded in 2018.

  • Where is Spectroplast's headquarters?

    Spectroplast's headquarters is located at Ruetistrasse 16, Zurich.

  • What is Spectroplast's latest funding round?

    Spectroplast's latest funding round is Incubator/Accelerator.

  • How much did Spectroplast raise?

    Spectroplast raised a total of $1.62M.

  • Who are the investors of Spectroplast?

    Investors of Spectroplast include Venturelab, IMD Startup Competition, Formnext Start-up Challenge, AM Ventures, EIC Accelerator and 4 more.

  • Who are Spectroplast's competitors?

    Competitors of Spectroplast include Oxford Performance Materials and 4 more.

Compare Spectroplast to Competitors

Pegasus Biologics

Pegasus Biologics is developing advanced bioimplants for soft tissue reinforcement for orthopedics, sports medicine, neurosurgical and spine applications

TissueTech Logo

TissueTech provides regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets. AmnioGraft, AmnioGuard, and PROKERA are cryopreserved amniotic membrane grafts processed using the CRYOTEK Method to ensure that the tissue is able to deliver anti-inflammatory, anti-angiogenic, anti-scarring, and wound healing actions.

Nano Carrier

Nano Carrier is a biotech company using nanotechnology to improve patient Quality of Life with a focus on cancer.

Cell Therapeutics

CTI is committed to developing, acquiring, and commercializing innovative treatments for cancer. In the company's pursuit of making cancer more treatable, they are developing a diversified portfolio of oncology products focused on identifying and developing new, less toxic, and more effective ways to treat cancer.

Iconic Therapeutics

Iconic Therapeutics is a clinical-stage biopharmaceutical company dedicated to translating scientific knowledge into new medicines. The company's understanding of the role of the tissue factor in angiogenesis, inflammation, and malignancies has led it to a new approach to developing therapies for devastating diseases such as macular degeneration and cancer.

BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.